AstraZeneca’s $27 Billion TTR Wipeout Hands Alnylam the Market — But Its Own Trial Has the Same Flaw — BigGo Finance
For AstraZeneca, July 9 was a $27 billion disaster. Its gene-silencing heart drug, eplontersen, had just flopped in…
Gene-Silencing Drug Wainua Fails Landmark ATTR-CM Trial in AstraZeneca Setback
AstraZeneca and Ionis Pharmaceuticals disclosed Thursday morning that their gene-silencing drug Wainua (eplontersen) failed the largest clinical trial…